Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators of signal transduction mediated by these second messenger molecules.
### Phosphodiesterase (PDE) Inhibitors & Modulators

#### (R)-(-)-Rolipram

**Cat. No.: HY-16900A**

- **Bioactivity:** (R)-(-)-Rolipram is the R-enantiomer of Rolipram. Rolipram is a selective inhibitor of phosphodiesterases PDE4 with \( IC_{50} \) of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.
- **Purity:** 99.85%
- **Clinical Data:** Phase 1
- **Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg

#### (S)-(+) Rolipram

**Cat. No.: HY-B0392**

- **Bioactivity:** (S)-(+) Rolipram is a PDE4-inhibitor and an anti-inflammatory agent, less potent than its R enantiomer.
- **Purity:** 99.85%
- **Clinical Data:** No Development Reported
- **Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

#### AMG 579

**Cat. No.: HY-12913**

- **Bioactivity:** AMG 579 is a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A) with an \( IC_{50} \) of 0.1 nM.
- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 250 mg, 500 mg

#### AN3199

**Cat. No.: HY-19830**

- **Bioactivity:** AN3199 is a PDE4 inhibitor with \( IC_{50} \) of 94.5 nM.
- **Purity:** 98.0%
- **Clinical Data:** No Development Reported
- **Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

#### Apremilast

**Cat. No.: HY-12085**

- **Bioactivity:** Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an \( IC_{50} \) of 74 nM.
- **Purity:** 99.95%
- **Clinical Data:** Launched
- **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

#### Anagrelide hydrochloride

**Cat. No.: HY-80523A**

- **Bioactivity:** Anagrelide Hydrochloride (BL4162A) is a drug used for the treatment of essential thrombocytosis.
- **Purity:** 99.75%
- **Clinical Data:** Launched
- **Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

#### Aminophylline

**Cat. No.: HY-B0140**

- **Bioactivity:** Aminophylline is a competitive nonselective phosphodiesterase inhibitor that is used to treat airway obstruction from asthma or COPD. Target: Phosphodiesterase Aminophylline is a compound of the bronchodilator theophylline with ethylenediamine in 2:1 ratio. The ethylenediamine improves solubility, and the...
- **Purity:** 99.56%
- **Clinical Data:** Launched
- **Size:** 10mM x 1mL in DMSO, 100 mg, 500 mg

#### Avanafil

**Cat. No.: HY-18252**

- **Bioactivity:** Avanafil (TA-1790) is a potent and highly selective phosphodiesterase-5 (PDE-5) inhibitor with \( IC_{50} = 5.2 \) nM for erectile dysfunction; lower selectivity against PDE1, PDE6, and PDE11.
- **Purity:** 98.28%
- **Clinical Data:** Launched
- **Size:** 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg

#### Autotaxin modulator 1

**Cat. No.: HY-12812**

- **Bioactivity:** Autotaxin modulator 1 is a novel Autotaxin modulator extracted from Patent WO 2014018881 A1.
- **Purity:** 99.94%
- **Clinical Data:** No Development Reported
- **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

#### Balipodect

**Cat. No.: HY-12472**

- **Bioactivity:** Balipodect (TAK-063) is a highly potent, selective and orally active PDE10A inhibitor with \( IC_{50} \) of 0.30 nM; >15000-fold selectivity over other PDEs.
- **Purity:** 98.04%
- **Clinical Data:** Phase 2
- **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

Tel: 609-228-6898  Fax: 609-228-5909  Email: sales@MedChemExpress.com
Bay 60-7550 (BAY 607550)  
Cat. No.: HY-14992

Bioactivity: Bay 60-7550 is a potent and selective PDE2 inhibitor with a $K_i$ of 3.8 nM.

Purity: 98.12%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 100 mg

BAY 73-6691 (BAY-73-6691)  
Cat. No.: HY-104028

Bioactivity: BAY 73-6691 is a potent, selective brain penetrant PDE9A inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BAY 73-6691 racemate  
Cat. No.: HY-104028A

Bioactivity: BAY 73-6691 racemate is a phosphodiesterase 9 inhibitor extracted from patent WO 2017070293 A1.

Purity: 99.84%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BPN14770  
Cat. No.: HY-117571

Bioactivity: BPN14770 is a selective phosphodiesterase 4D (PDE4D) allosteric inhibitor with $IC_{50}$s of 7.8 nM and 7.4 nM for PDE4D7 and PDE4D3 (two different dimeric forms of PDE4D), respectively.[1]

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BW-A 78U  
Cat. No.: HY-100118

Bioactivity: BW-A 78U is a PDE4 inhibitor with an $IC_{50}$ of 3 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg

CI-1044 (PD-189659)  
Cat. No.: HY-100246

Bioactivity: CI-1044 is an orally active PDE4 inhibitor with $IC_{50}$s of 0.29, 0.08, 0.56, 0.09 μM for PDE4A5, PDE4B2, PDE4C2 and PDE4D3, respectively.

Purity: 98.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg

Cilomilast (SB-207499)  
Cat. No.: HY-10790

Bioactivity: Cilomilast (SB-207499; Ariflo) is a potent PDE4 inhibitor with $IC_{50}$ of about 110 nM, has anti-inflammatory activity and low central nervous system activity.

Purity: 98.81%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

BI-409306  
Cat. No.: HY-112831

Bioactivity: BI-409306 is a potent and selective PDE9A inhibitor, with an $IC_{50}$ of 52 nM, and shows weak activity against other PDEs, such as PDE1A ($IC_{50}$ 1.4 μM), PDE1C ($IC_{50}$ 1.0 μM), PDE2A, PDE3A, PDE4B, PDE5A, PDE6A8, PDE7A, and PDE10A ($IC_{50}$ all &…

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BRL-50481  
Cat. No.: HY-109586

Bioactivity: BRL-50481 is a novel and selective inhibitor of PDE7 with $IC_{50}$s of 0.15, 12.1, 62 and 490 μM for PDE7A, PDE7B, PDE4 and PDE3, respectively.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CDC801  
Cat. No.: HY-U00179

Bioactivity: CDC801 is a potent and orally active phosphodiesterase 4 (PDE4) and tumor necrosis factor-α (TNF-α) inhibitor with $IC_{50}$s of 1.1 μM and 2.5 μM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

CI-1044  
Cat. No.: HY-100246

Bioactivity: CI-1044 is an orally active PDE4 inhibitor with $IC_{50}$s of 0.29, 0.08, 0.56, 0.09 μM for PDE4A5, PDE4B2, PDE4C2 and PDE4D3, respectively.

Purity: 98.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg

Cilomilast (SB-207499)  
Cat. No.: HY-10790

Bioactivity: Cilomilast (SB-207499; Ariflo) is a potent PDE4 inhibitor with $IC_{50}$ of about 110 nM, has anti-inflammatory activity and low central nervous system activity.

Purity: 98.81%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

www.MedChemExpress.com
**Bioactivity:** Cilostamide is a selective and potent PDE3 inhibitor, with \( IC_{50} \) values of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity.

**Purity:** 99.63%

**Clinical Data:** No Development Reported

**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**Bioactivity:** Cilostazol(OPC 13013; OPC 21) is a potent inhibitor of PDE3A, the isoform of PDE 3 in the cardiovascular system (IC50=0.2 uM); IC50 Value: 0.2 uM [1]. Target: PDE3A in vitro: Cilostazol caused a concentration-dependent increase in the cAMP level in rabbit and human platelets with similar potency. Furthermore...

**Purity:** 99.34%

**Clinical Data:** No Development Reported

**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

---

**Bioactivity:** CM-675 is a dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitor, with IC\(_{50}\) values of 114 nM and 673 nM for PDE5 and HDAC1, respectively. CM-675 has potential to treat Alzheimer’s disease [1].

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 10 mg, 25 mg, 50 mg, 100 mg

---

**Bioactivity:** Crisaborole (AN-2728; PF-06930164) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC\(_{50}\) of 0.49 μM.

**Purity:** 99.97%

**Clinical Data:** Phase 3

**Size:** 10 mM x 1 mL in DMSO, 10 mg, 50 mg, 100 mg

---

**Bioactivity:** D159687 is a selective PDE4D inhibitor.[1]

**Purity:** 98.00%

**Clinical Data:** No Development Reported

**Size:** 10 mM x 1 mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg

---

**Bioactivity:** Deltarasin is an inhibitor of KRAS-PDEδ interaction with \( K_d \) of 38 nM for binding to purified PDEδ.

**Purity:** 95.95%

**Clinical Data:** No Development Reported

**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

**Bioactivity:** Deltarasin hydrochloride is an inhibitor of KRAS-PDEδ interaction with \( K_d \) of 38 nM for binding to purified PDEδ.

**Purity:** 99.97%

**Clinical Data:** No Development Reported

**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

**Bioactivity:** Deltasonamide 2 is a PDE δ inhibitor with a \( K_d \) of \(-385\) pM and an EC\(_{50}\) of 1.24 μM [1].

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 5 mg, 10 mg, 50 mg, 100 mg

---

**Bioactivity:** Deltasonamide 2 TFA is a PDE δ inhibitor with a \( K_d \) of \(-385\) pM and an EC\(_{50}\) of 1.24 μM [1].

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:**
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diphylline</strong>&lt;sup&gt; (Diprophylline) &lt;/sup&gt;</td>
<td>HY-B0128</td>
</tr>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Dyphylline acts as an adenosine receptor antagonist and phosphodiesterase inhibitor, which is used in the treatment of respiratory disorders.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.28%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 100 mg, 500 mg</td>
</tr>
<tr>
<td><strong>Dipyridamole</strong></td>
<td>HY-B0312</td>
</tr>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>98.02%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 100 mg, 500 mg</td>
</tr>
<tr>
<td><strong>Doxofylline</strong></td>
<td>HY-80004</td>
</tr>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Doxofylline is an antagonist of adenosine A1 receptor which also inhibits phosphodiesterase IV.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.88%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 100 mg</td>
</tr>
<tr>
<td><strong>ER21355</strong></td>
<td>HY-101826</td>
</tr>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>ER21355 is an inhibitor of phosphodiesterase 5 (PDE5), used for treatment of prostatic diseases.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td><strong>Fraxin</strong>&lt;sup&gt; (Fraxoside) &lt;/sup&gt;</td>
<td>HY-N0579</td>
</tr>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Fraxin isolated from Acer tegmentosum, F. ormus or A. hippocastanum, is a glucoside of fraxxin and reported to exert potent anti-oxidative stress action&lt;sup&gt;[3]&lt;/sup&gt;, anti-inflammatory and antimetastatic properties. Fraxin shows its antioxidative effect through inhibition of cyclic AMP...</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>5 mg, 10 mg, 25 mg</td>
</tr>
<tr>
<td><strong>GSK256066</strong></td>
<td>HY-10469</td>
</tr>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC&lt;sub&gt;50&lt;/sub&gt; of 3.2 pM, &gt;380,000-fold selectivity versus PDE1/2/3/5/6 and &gt;2500-fold selectivity against PDE4B versus PDE7.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>98.11%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Phase 2</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td><strong>GSK 256066 Trifluoroacetate</strong>&lt;sup&gt; (GSK256066 (2,2,2-trifluoroacetic acid)) &lt;/sup&gt;</td>
<td>HY-70069</td>
</tr>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>GSK 256066 Trifluoroacetate is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC&lt;sub&gt;50&lt;/sub&gt; of 3.2 pM, &gt;380,000-fold selectivity versus PDE1/2/3/5/6 and &gt;2500-fold selectivity against PDE4B versus PDE7.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>98.94%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Phase 2</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
</tr>
<tr>
<td><strong>IBMX</strong>&lt;sup&gt; (3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine) &lt;/sup&gt;</td>
<td>HY-12318</td>
</tr>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor, with IC&lt;sub&gt;50&lt;/sub&gt; of 6.5, 26.3 and 31.7 μM for PDE3, PDE4 and PDE5, respectively.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.99%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Phase 2</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 50 mg</td>
</tr>
<tr>
<td><strong>HA130</strong></td>
<td>HY-19329</td>
</tr>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>HA130 is a selective ATX (autotaxin) inhibitor with IC&lt;sub&gt;50&lt;/sub&gt; of 28 nM. IC&lt;sub&gt;50&lt;/sub&gt; value: 28 nM&lt;sup&gt;[2]&lt;/sup&gt; Target: ATX in vitro: HA130 completely blocks the ability of ATX to promote TEM (transendothelial migration). HA130 at 0.3 μM completely ablates the activity of ATX on TK1 uropod formation.</td>
</tr>
</tbody>
</table>
Icariin (Ieariline)  
Cat. No.: HY-N0014

**Bioactivity:** Icariin is a flavonol glycoside. Icariin inhibits PDE5 and PDE4 activities with IC\textsubscript{50} of 432 nM and 73.50 μM, respectively. Icariin also is a PPAR\alpha activator.

**Purity:** 98.75%

**Clinical Data:** Phase 2

**Size:** 10mM x 1mL in DMSO, 5 mg, 20 mg, 50 mg, 100 mg

---

ICI 153110  
Cat. No.: HY-100239

**Bioactivity:** ICI 153110 is an orally active phosphodiesterase inhibitor with both vasodilating and inotropic properties which is designed for the treatment of congestive cardiac failure.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

---

Irsogladine (Dicloguamine)  
Cat. No.: HY-B0327

**Bioactivity:** Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.

**Purity:** 95.13%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 100 mg, 500 mg

---

Irsogladine maleate (Dicloguamine maleate; MN1695)  
Cat. No.: HY-B0327A

**Bioactivity:** Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.

**Purity:** >98%

**Clinical Data:** Launched

**Size:** 100 mg, 500 mg

---

ITI-214  
Cat. No.: HY-12501A

**Bioactivity:** ITI-214 is a picomolar PDE1 inhibitor with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels, exhibits potent PDE1 inhibitory activity (Ki = 58 pM).

**Purity:** 99.58%

**Clinical Data:** Phase 1

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

ITI-214 free base  
Cat. No.: HY-12501

**Bioactivity:** ITI-214 (free base) is a picomolar PDE1 inhibitor with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels, exhibits potent PDE1 inhibitory activity (Ki = 58 pM).

**Purity:** 98.0%

**Clinical Data:** Phase 1

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

K134 (OPC33509)  
Cat. No.: HY-U00186

**Bioactivity:** K134 is a phosphodiesterase 3 (PDE3) inhibitor. The IC\textsubscript{50} of K134 toward PDE3A, PDE3B, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 μM, respectively.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg, 20 mg

---

L791943  
Cat. No.: HY-U00254

**Bioactivity:** L791943 is a potent, selective phosphodiesterase-4 (PDE4) inhibitor with an IC\textsubscript{50} of 4.2 nM.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

---

LAS-31180  
Cat. No.: HY-101811

**Bioactivity:** LAS-31180 is an inhibitor of phosphodiesterase 3, with positive inotropic and vasodilator properties.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg, 20 mg

---

Lotamilast (RVT-501; E6005)  
Cat. No.: HY-12740

**Bioactivity:** Lotamilast (RVT-501; E6005) is a selective phosphodiesterase 4 (PDE4) inhibitor with an IC\textsubscript{50} of 2.8 nM.

**Purity:** 98.0%

**Clinical Data:** Phase 2

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>Name</th>
<th>Bioactivity</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>HY-50098</td>
<td>Mardepodect (PF-2545920)</td>
<td>Mardepodect hydrochloride (PF-2545920 (hydrochloride))&lt;br&gt;&lt;br&gt;<strong>Bioactivity:</strong> Mardepodect hydrochloride (PF-2545920 hydrochloride) is a potent and selective PDE10A inhibitor with IC(_50) of 0.37 nM, with &gt;1000-fold selectivity over the PDE.&lt;br&gt;&lt;br&gt;Purity: 95.00%&lt;br&gt;Clinical Data: No Development Reported&lt;br&gt;Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
<td>99.89%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>HY-14252</td>
<td>Milrinone (Win 47203)</td>
<td>Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.</td>
<td>99.78%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 50 mg, 100 mg</td>
</tr>
<tr>
<td>HY-14930A</td>
<td>Mirodenafil dihydrochloride (SK-3530 dihydrochloride)</td>
<td>Mirodenafil (SK3530) is a phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction.</td>
<td>99.79%</td>
<td>Launched</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>HY-100933</td>
<td>MY-5445</td>
<td>MY-5445 is a specific phosphodiesterase type 5 (PDE5) inhibitor [1].</td>
<td>99.79%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg</td>
</tr>
<tr>
<td>HY-19102</td>
<td>NSP-805</td>
<td>NSP-805 is a potent and selective inhibitor of guinea pig cardiac phosphodiesterase 3 (PDE3), and a cardiotonic agent with vasodilator properties.</td>
<td>99.0%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td>HY-15178</td>
<td>Oglemilast (GRC 3886)</td>
<td>Oglemilast(GRC3886) is a potent PDE4 inhibitor, under clinical studies in the treatment of allergen-induced asthma.</td>
<td>96.83%</td>
<td>Phase 2</td>
<td>5 mg, 10 mg, 50 mg</td>
</tr>
</tbody>
</table>
Olprinone (Loprinone)  
Cat. No.: HY-14254A

Bioactivity: Olprinone (Loprinone) is a selective phosphodiesterase 3 (PDE3) inhibitor.

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg

PAT-505
Cat. No.: HY-107781

Bioactivity: PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC$_{50}$ of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PDE-9 inhibitor
Cat. No.: HY-50865

Bioactivity: PDE-9 inhibitor is useful for neurodegenerative diseases.

Purity: 99.29%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

PAT-505
Cat. No.: HY-107781

Bioactivity: PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC$_{50}$ of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

PDE1-IN-2
Cat. No.: HY-101490

Bioactivity: PDE1-IN-2 is an inhibitor of PDE1 extracted from patent WO2016/55618 A1, example 31, has IC$_{50}$ values of 6, 140 and 164 nM for PDE1C, PDE1B and PDE1A, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 20 mg

PDE2/PDE10-IN-1
Cat. No.: HY-U00427

Bioactivity: PDE2/PDE10-IN-1 is a phosphodiesterase 2 (PDE2) and PDE10 inhibitor with IC$_{50}$ of 29 and 480 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PDE5-IN-2
Cat. No.: HY-112704

Bioactivity: PDE5-IN-2 is a potent, highly selective, and orally active PDE5 inhibitor, with an IC$_{50}$ of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC$_{50}$ of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arter...

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg
PDE9-IN-1

Cat. No.: HY-126137

Bioactivity: PDE9-IN-1 is a potent, selective, and orally bioavailable phosphodiesterase-9A (PDE9A) inhibitor with an IC$_{50}$ of 8.7 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Pentoxifylline

(BL-191; PTX; Oxpentifylline)

Cat. No.: HY-80715

Bioactivity: Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor. Target: PDE Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate...

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 1 g

PF-04447943

Cat. No.: HY-15441

Bioactivity: PF-04447943 is a potent inhibitor of human recombinant PDE9A (IC$_{50}$=12 nM) with >78-fold selectivity, respectively, over other PDE family members (IC$_{50}$>1000 nM).

Purity: 99.84%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

PF-04957325

Cat. No.: HY-15426

Bioactivity: PF-04957325 is a highly potent and selective PDE8 inhibitor, with IC$_{50}$ of 0.7 nM and 0.3 nM for PDE8A and PDE8B, respectively.

Purity: 98.48%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

PF-05085727

Cat. No.: HY-102050

Bioactivity: PF-05085727 is a potent, selective and brain penetrant Phosphodiesterase 2A (PDE2A) inhibitor with an IC$_{50}$ of 2 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PF-05180999

Cat. No.: HY-111371

Bioactivity: PF-05180999 is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC$_{50}$ of 1.6 nM.

Purity: 99.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-8380

Cat. No.: HY-13344

Bioactivity: PF-8380 is a potent autotaxin inhibitor with an IC$_{50}$ of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.

Purity: 98.49%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

PF-8380 hydrochloride

Cat. No.: HY-13344A

Bioactivity: PF-8380 hydrochloride is a potent autotaxin inhibitor with an IC$_{50}$ of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Pimobendan

(UD-CG115)

Cat. No.: HY-80204

Bioactivity: Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC$_{50}$ of 0.32 μM.

Purity: 99.51%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

Pimobendan hydrochloride

(UD-CG115 (hydrochloride))

Cat. No.: HY-80204A

Bioactivity: Pimobendan (hydrochloride) (UD-CG115 (hydrochloride)) is a selective inhibitor of PDE3 with IC$_{50}$ of 0.32 μM.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg
<table>
<thead>
<tr>
<th><strong>Prinoxodan (RGW2938)</strong></th>
<th><strong>Cat. No.: HY-U00208</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Prinoxodan (RGW2938) is a <strong>phosphodiesterase</strong> inhibitor.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>95.58%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Revizinone (R80122)</strong></th>
<th><strong>Cat. No.: HY-100615</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Revizinone is a novel selective phosphodiesterase (PDE) inhibitor with IC50 values on this enzyme to 0.036 microM. Target: phosphodiesterase (PDE)[3]; IC 50: 0.036 microM. [3] In vivo: The administration of Revizinone improved the haemodynamic profile with an increase in cardiac output, a...</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>98.10%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Roflumilast</strong></th>
<th><strong>Cat. No.: HY-15455</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Roflumilast is a selective <strong>PDE4</strong> inhibitor with IC50 of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDE4A4, PDE4B1, and PDE4B2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.97%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Roflumilast N-oxide</strong></th>
<th><strong>Cat. No.: HY-100639</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Roflumilast N-oxide is a <strong>PDE type 4</strong> inhibitor.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.69%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Saterinone hydrochloride (BDF 8634 hydrochloride)</strong></th>
<th><strong>Cat. No.: HY-101644A</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Saterinone hydrochloride is a <strong>phosphodiesterase III (PDE III)</strong> inhibitor.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Sch59498</strong></th>
<th><strong>Cat. No.: HY-U00374</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Sch59498 is a potent inhibitor of <strong>phosphodiesterase 1c (Pde1c)</strong>.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>1 mg, 5 mg, 10 mg</td>
</tr>
</tbody>
</table>

---

Bioactivity: Prinoxodan (RGW2938) is a phosphodiesterase inhibitor.

Bioactivity: R 80123 is the Z-isomer of R 79595, is also a highly selective phosphodiesterase inhibitor. The function is similar to R 80122 (HY-100615, Revizinone). In vivo: The administration of Revizinone improved the haemodynamic profile with an increase in cardiac output, a decrease in systemic vascular resistance...

Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg, 10 mg

Bioactivity: Ro-15-2041 is a selective platelet phosphodiesterase inhibitor with antithrombotic properties.

Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg, 10 mg, 20 mg

Bioactivity: Roflumilast Impurity E is the impurity of Roflumilast.

Roflumilast(Daliresp) is a drug which acts as a selective and long-acting inhibitor of the enzyme PDE-4 with an IC50 value of 0.8 nM.

Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg, 10 mg

Bioactivity: Roflumilast N-oxide is a PDE type 4 inhibitor.

Bioactivity: Rolipram is a selective phosphodiesterases PDE4 inhibitor with IC50 of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

Purity: 99.56%

Clinical Data: Phase 2

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

Bioactivity: Rolipram is a selective phosphodiesterases PDE4 inhibitor with IC50 of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

Purity: 99.56%

Clinical Data: Phase 2

Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

Bioactivity: Rolipram is a selective phosphodiesterases PDE4 inhibitor with IC50 of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.
**SDZ-MKS 492**  
(MKS 492)  
Cat. No.: HY-100164  
**Bioactivity:** SDZ-MKS 492 (MKS 492) is a selective type III isozyme inhibitor of cyclic nucleotide phosphodiesterase, effective in allergic bronchoconstriction and platelet activating factor (PAF) or LTB4-induced inflammatory reactions in animals.\[1\].  
**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 500 mg, 250 mg

**Senazodan**  
Cat. No.: HY-101693  
**Bioactivity:** Senazodan is a Ca\(^{2+}\) sensitiser, and also shows inhibition effect on PDE III.  
**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg, 10 mg, 20 mg

**Sildenafil**  
(UK-92480)  
Cat. No.: HY-15025  
**Bioactivity:** Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC\(_{50}\) of 5.22 nM.  
**Purity:** 99.89%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg

**Sildenafil citrate**  
(UK-92480 citrate)  
Cat. No.: HY-15025A  
**Bioactivity:** Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC\(_{50}\) of 5.22 nM.  
**Purity:** 99.84%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg

**Sophoflavescenol**  
Cat. No.: HY-N2284  
**Bioactivity:** Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with IC\(_{50}\) of 0.013 µM against Phosphodiesterase 5 (PDE5), and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC\(_{50}\) of 0.30 µM, 0.17 µM, 17...  
**Purity:** 98.15%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg

**Tadalafil**  
(IC-351)  
Cat. No.: HY-90009A  
**Bioactivity:** Tadalafil (IC-351) is a PDE5 inhibitor with an IC\(_{50}\) value of 1.8 nM.  
**Purity:** 99.93%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg

**Theodrenaline**  
((±)-Theodrenaline)  
Cat. No.: HY-U00344  
**Bioactivity:** Theodrenaline is a cardiac stimulant, also acts as an anti-hypotensive agent together with cafedrine.  
**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 1 mg, 5 mg, 10 mg, 20 mg

**Theophylline**  
(1,3-Dimethylxanthine; Theo-24)  
Cat. No.: HY-80809  
**Bioactivity:** Theophylline is a nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor blocker, and histone deacetylase (HDAC) activator.  
**Purity:** 99.94%  
**Clinical Data:** Launched  
**Size:** 10mM x 1mL in DMSO, 5 g

**Tibenelast sodium**  
(LY 186655)  
Cat. No.: HY-101705  
**Bioactivity:** Tibenelast sodium is a phosphodiesterase inhibitor.  
**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg, 10 mg, 20 mg

**TP-10**  
Cat. No.: HY-14550  
**Bioactivity:** TP-10 is a PDE10A inhibitor with IC\(_{50}\) of 0.8 nM.  
**Purity:** 98.54%  
**Clinical Data:** Phase 2  
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
<table>
<thead>
<tr>
<th><strong>Bioactivity</strong></th>
<th><strong>Cat. No.</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TPN171</strong></td>
<td>HY-128593</td>
</tr>
<tr>
<td><strong>Bioactivity</strong></td>
<td>TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC$_{50}$ of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH) [1].</td>
</tr>
<tr>
<td><strong>Purity</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size</strong></td>
<td>100 mg, 250 mg, 500 mg</td>
</tr>
<tr>
<td><strong>Bioactivity</strong></td>
<td>Udenafil(DA8159) is a PDE5 inhibitor used in urology to treat erectile dysfunction.</td>
</tr>
<tr>
<td><strong>Purity</strong></td>
<td>99.73%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td><strong>Bioactivity</strong></td>
<td>Vardenafil is a PDE5 inhibitor used for treating erectile dysfunction.</td>
</tr>
<tr>
<td><strong>Purity</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size</strong></td>
<td>100 mg, 200 mg</td>
</tr>
<tr>
<td><strong>Bioactivity</strong></td>
<td>Vesnarinone is a quinoline derivative, and its pharmacodynamic effects include inhibition of phosphodiesterase III (PDE3) activity, increases in calcium flux and decreases in potassium flux.</td>
</tr>
<tr>
<td><strong>Purity</strong></td>
<td>96.06%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td><strong>Bioactivity</strong></td>
<td>Vardenafil HCl is a PDE5 inhibitor used for treating erectile dysfunction.</td>
</tr>
<tr>
<td><strong>Purity</strong></td>
<td>98.62%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size</strong></td>
<td>10mM x 1mL in DMSO, 100 mg, 200 mg</td>
</tr>
<tr>
<td><strong>Bioactivity</strong></td>
<td>Vinpocetine(Ethyl apovincaminate) is a selective for PDE1 (IC$<em>{50}$ = 21 μM). Also blocks voltage-gated Na+ channels. IC$</em>{50}$ value: Target: PDE1; Na+ channel</td>
</tr>
<tr>
<td><strong>Purity</strong></td>
<td>99.82%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>Launched</td>
</tr>
<tr>
<td><strong>Size</strong></td>
<td>10mM x 1mL in DMSO, 50 mg, 100 mg, 200 mg, 500 mg</td>
</tr>
<tr>
<td><strong>Bioactivity</strong></td>
<td>WAY127093B racemate is the racemate of WAY127093B. WAY127093B is a novel, orally active phosphodiesterase IV inhibitor in guinea pigs and rats.</td>
</tr>
<tr>
<td><strong>Purity</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size</strong></td>
<td>500 mg, 250 mg</td>
</tr>
<tr>
<td><strong>Bioactivity</strong></td>
<td>Win 58237 is a cyclic nucleotide phosphodiesterase (PDE) inhibitor, with $K_{i}$ of 170 nM for PDE V, possessing vasorelaxant activity.</td>
</tr>
<tr>
<td><strong>Purity</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size</strong></td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td><strong>Bioactivity</strong></td>
<td>Zardaverine is a newly developed dual-selective PDE3/4 inhibitor with IC50 values of 0.5 uM and 0.8 uM respectively.</td>
</tr>
<tr>
<td><strong>Purity</strong></td>
<td>98.17%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
</tr>
</tbody>
</table>
Ziritaxestat (GLPG1690)  
Cat. No.: HY-101772

<table>
<thead>
<tr>
<th><strong>Bioactivity</strong></th>
<th>Ziritaxestat (GLPG1690) is a first-in-class autotaxin (ATX) inhibitor, with an IC$_{50}$ of 131 nM and K$_i$ of 15 nM.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purity</strong></td>
<td>99.97%</td>
</tr>
<tr>
<td><strong>Clinical Data</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size</strong></td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>